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 The cystic fibrosis (CF) community is witnessing great strides in the development of 
mutation-specific CF therapeutics.  In 2017, the cystic fibrosis transmembrane conductance 
regulator (CFTR) potentiator ivacaftor (KalydecoTM; VX-770; Vertex Pharmaceuticals) [1,2] 
became available to individuals with 38 CF-causing mutations 
(https://www.cff.org/News/News-Archive/2017/FDA-Approves-Ivacaftor-for-Five-Splice-
Mutations/), while early results of clinical trials of triple combination therapy using two 
CFTR correctors and ivacaftor for the most common CF mutation, F508del-CFTR, were 
highly encouraging (https://investors.vrtx.com/news-releases/news-release-details/vertex-
announces-positive-phase-1-phase-2-data-three-different).  It is anticipated that mutation-
specific therapies will soon become available to most individuals living with CF 
(https://www.nacfconference.org/Content/Archives/2017/Plenary_Session_I__Thursday,_No
vember_2,_2017/).  But, what about those individuals with CF mutations currently refractory 
to small molecule CFTR modulators? 
 
 One such mutation is N1303K, a mutation that disrupts CFTR delivery to, and 
stability at, the plasma membrane and function as a regulated Cl- channel, which is associated 
with a severe disease phenotype [3].  For several reasons, N1303K is highly deserving of 
attention from the CF community.  First, N1303K is among the more common rare CF 
mutation, being particularly prevalent in Mediterranean populations [4].  Second, N1303K 
affects a residue in nucleotide-binding domain 2 (NBD2) located in a similar region to 
F508del in NBD1 [5].  Third, N1303K-CFTR appears refractory to rescue by small molecule 
CFTR correctors (e.g. [6,7]).  Encouragingly, the current issue of the Journal publishes three 
N1303K studies, which advance greatly our understanding of how the mutation disrupts 
CFTR expression and function and inform therapeutic strategies to fully restore its function 
[8–10]. 
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 DeStefano and colleagues [8] comprehensively characterised the behaviour of 
N1303K-CFTR as a regulated Cl- channel.  Previous work had demonstrated that N1303K 
slows channel gating with the result that the frequency of channel openings is decreased 
greatly, but their duration noticeably prolonged [11].  They also suggest that N1303K 
moderately reduced open probability (Po), one measure of CFTR activity [11].  However, 
calculating the Po of mutant CFTR is frequently challenging because of uncertainty about the 
number of active channels present in cell-free membrane patches.  To overcome this technical 
difficulty, DeStefano et al. [8] used the efficacious CFTR potentiator GLPG1837, which 
enhances channel gating by a similar mechanism to ivacaftor [12], to accurately determine 
the number of active channels in membrane patches.  Using this approach, they found that 
N1303K-CFTR has a severe gating defect (Po ≤ 0.03), worse than that of F508del-CFTR, but 
akin to that of the gating mutation G551D-CFTR [13]. 
 
 To understand better how N1303K disrupts CFTR channel gating, DeStefano et al. [8] 
used high-affinity ATP analogues that strongly stimulate channel gating and site-directed 
mutations that either impede channel opening or delay channel closure [13].  In contrast to 
their effects on F508del-CFTR, the site-directed mutations and one ATP analogue were 
without effect on N1303K-CFTR channel gating, while the other ATP analogue, a “super” 
stimulator of CFTR channel gating [14], surprisingly inhibited N1303K-CFTR channel 
activity.  If these data were not enough, upon removal of ATP, N1303K-CFTR did not 
disappear in a flash like wild-type CFTR, but instead retained significant channel activity, 
reminiscent of the ATP-independent channel gating of G551D-CFTR (for review, see [13]).  
To explain these data, DeStefano et al. [8] employed the atomic-resolution structure of CFTR 
solved by Chen and colleagues using cryo-electron microscopy [5].  The authors 
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convincingly explain that N1303K causes uncoupling of the NBDs from the membrane-
spanning domains (MSDs), which form the channel pore, by preventing the correct 
positioning of ATP in ATP-binding site 2 and hence, formation of the NBD1:NBD2 dimer.  
They further explain that F508del also disrupts NBD1:NBD2 dimer formation, albeit by a 
different mechanism [15].  Thus, DeStafano et al. [8] demonstrate that N1303K is the CF 
mutation in NBD2 functionally equivalent to F508del in NBD1, albeit its gating defect is 
more severe than that of F508del-CFTR.  By distinct molecular mechanisms the two 
mutations disrupt communication between the NBDs and the MSDs, with the result that 
CFTR becomes a rusty gate. 
 
 Using CF bronchial epithelial cells (CFBE41o-) engineered to express low levels of 
N1303K-CFTR, Liu and colleagues [9] investigated how the mutation prevents CFTR 
delivery to the plasma membrane and the action of CFTR correctors, which rescue misfolded 
F508del-CFTR.  In previous work [16], the authors found that short-term culture at low 
temperature fails to rescue the plasma membrane expression of N1303K-CFTR in contrast to 
the effects of this well-known laboratory trick on F508del-CFTR.  Based on this result and 
other observations, Rapino et al. [16] speculated that misfolded F508del- and N1303K-CFTR 
are processed differently by cells. 
 
 F508del-CFTR is associated with defective autophagy, leading to the intracellular 
accumulation of misfolded CFTR protein and hence, lung inflammation [17].  Using 
pharmacological tools, Liu et al. [9] found that the N1303K mutation arrests autophagy.  The 
authors discovered immature N1303K-CFTR protein associated with autophagosomes, but 
not degraded by autophagosome fusion with lysosomes and enzymatic digestion.  Upon 
treatment with the CFTR correctors corr-4a (CF Foundation Therapeutics CFTR Compound 
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Program reference no. C4; [18]) and C18 (a lumacaftor analogue; [19]), which target distinct 
molecular defects in misfolded CFTR, the association of N1303K-CFTR with 
autophagosomes was reduced, leading to the production of more mature CFTR protein.  
However, this mature protein was degraded by lysosomes with the result that little functional 
N1303K-CFTR protein was detected at the plasma membrane [9].  Thus, the authors’ data 
caution that different CF mutations have distinct effects on the biosynthesis of CFTR and its 
intracellular transport with implications for therapy development.  They also emphasize the 
difficulty of developing small molecule CFTR modulators that fully restore function to 
N1303K-CFTR. 
 
 To squeeze as much activity as possible out of the few N1303K-CFTR Cl- channels 
present at the plasma membrane, Phuan and colleagues [10] advanced the idea of 
combination potentiator (‘co-potentiator’) therapy using small molecules that act additively 
or synergistically with ivacaftor.  Based on their previous success hunting for small molecule 
CFTR modulators of W1282X-CFTR [20], Phuan et al. [10] performed a synergy screen of 
16,000 small molecules by acutely treating butyrate-rescued N1303K-CFTR with ivacaftor 
and test compounds.  Although the authors identified five active small molecules, all were 
less effective co-potentiators of N1303K-CFTR than the arylsulfonamide-pyrrolopyridine 
ASP-11 (formerly called W1282Xpot-A15; [20]), which robustly synergised with ivacaftor to 
restore near wild-type levels of activity to W1282X-CFTR as measured with the Ussing 
chamber technique.  Importantly, ivacaftor and ASP-11 co-potentiated N1303K-CFTR in 
human nasal epithelial (hNE) cells homozygous for the N1303K mutation, restoring levels of 
CFTR function equivalent to ~18% of those achieved in non-CF hNE cells, an impressive 
amount given the great difficulty of coaxing the mutant protein to the plasma membrane [10].  
Because of the severity of the N1303K processing defect and its insensitivity to CFTR 
6 
 
correctors, the authors caution the Reader not to overinterpret the potential clinical benefit of 
their data.  Nevertheless, their data are very encouraging for two further reasons.  First, ASP-
11 activated wild-type CFTR in the absence of the cAMP agonist forskolin, raising the 
possibility that it has a unique mechanism of action.  Second, through their medicinal 
chemistry efforts the authors identified a more potent arylsulfonamide-pyrrolopyridine, ASP-
08, with favourable drug-like properties to oil N1303K-CFTR’s rusty gate. 
 
 In conclusion, the three studies of N1303K published in the current issue of the 
Journal remind us that careful studies of the molecular mechanisms of CFTR dysfunction are 
crucial to the development of transformational therapies for all individuals living with CF.  
We are confident that they will stimulate new research, which will ultimately directly benefit 
individuals living with CF and N1303K-CFTR.  Let’s take action today! 
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